Incredibly, M-Sig achieved a consistent hazard ratio of approximately 2.5–3, with highly significant p-values in all five clinical cohorts despite completely different sample procurement, processing, and gene expression platforms including RNAseq.
← all excerpts
Development and validation of a novel platform-independent metastasis signature in human breast cancer.
1
—
—